Enclomiphene vs TRT: How They Differ

When men compare enclomiphene vs TRT, the core difference is mechanism. Enclomiphene is an oral selective estrogen receptor modulator (SERM) that is used in an effort to raise the body’s own luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone while preserving sperm production. Testosterone replacement therapy (TRT) instead delivers testosterone from outside the body, which can suppress the hypothalamic-pituitary-gonadal (HPG) axis and reduce sperm production and testicular function. An important regulatory point up front: compounded enclomiphene is not FDA-approved for any use, and all use in men is off-label. FDA-approved testosterone products are indicated for men with certain forms of hypogonadism (congenital or acquired primary, or hypogonadotropic) due to an associated medical condition, and the FDA has not established their safety or efficacy for age-related low testosterone. Both are prescription-only and require evaluation by a licensed provider.

Enclomiphene vs TRT at a glance

The two approaches aim at the same symptom picture from opposite directions. One tries to stimulate your own hormone production; the other supplies the hormone directly. Neither is right for everyone, and outcomes vary from person to person.

Factor	Compounded enclomiphene	TRT (testosterone replacement therapy)
What it is	Oral SERM; the trans-isomer (E-isomer) of clomiphene citrate	Exogenous testosterone delivered from outside the body
How it works	Blocks estrogen receptors at the hypothalamus and pituitary, reducing negative feedback so GnRH and then LH and FSH rise, stimulating the testes to make more endogenous testosterone	Adds testosterone directly, which can suppress LH and FSH and intratesticular testosterone
Effect on fertility	In small, short-term studies in secondary hypogonadism, raised testosterone, LH and FSH while preserving sperm counts; not an FDA-approved fertility treatment	Can impair spermatogenesis and may cause testicular atrophy and infertility; AUA and ASRM recommend against testosterone monotherapy in men trying to conceive
Administration	Oral, typically once daily	Injections, gels, or pellets, depending on the FDA-approved product
FDA status	Not FDA-approved for any indication; off-label; prescription only via 503A compounding	FDA-approved testosterone products exist for certain forms of hypogonadism due to an associated medical condition; compounded testosterone is not FDA-approved
Key labeled risks (SERM class / TRT)	Visual disturbances that may be prolonged or irreversible; thromboembolic events per the clomiphene label	Polycythemia or elevated hematocrit, fertility suppression, prostate and PSA considerations; topical gels carry a boxed warning on secondary exposure to children, and labels address abuse and dependence

What is enclomiphene?

Enclomiphene is the trans-isomer (E-isomer) of clomiphene citrate. Clomid, the branded clomiphene product, is a mixture of approximately 62% enclomiphene (the trans-isomer) and 38% zuclomiphene (the cis, longer-acting estrogenic isomer); the FDA clomiphene label describes the cis-isomer or zuclomiphene content as roughly 30% to 50%. As a SERM, enclomiphene antagonizes estrogen receptors at the hypothalamus and pituitary. By reducing estrogen’s negative feedback, it is intended to allow GnRH to rise, which in turn raises LH and FSH, signaling the testes to produce more of the body’s own testosterone. It is taken orally, typically once daily.

It is important to be clear about regulatory status. Enclomiphene citrate is not an FDA-approved drug, and no enclomiphene product, compounded or manufactured, has FDA approval for any indication, including low testosterone, hypogonadism, or fertility. The only branded enclomiphene product, Repros Therapeutics’ Androxal, received an FDA Complete Response Letter in December 2015 for secondary hypogonadism in overweight men; the FDA said the Phase 3 study design was no longer adequate to show clinical benefit and asked for additional studies. Those studies were never completed, and development was later discontinued.

On the FDA Section 503A bulk drug substances list, which is periodically revised, enclomiphene citrate has been placed in Category 1 (under evaluation). Confirm the current status with the latest FDA list before relying on it. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted on June 8, 2022 against adding enclomiphene citrate to the final 503A Bulks List, and the substance is not on that final list. Category 1 is not FDA approval. Under the FDA’s interim policy, the agency has stated it does not intend to take enforcement action against compounders using Category 1 substances under specified conditions; this interim status is unsettled, and the FDA stopped assigning new interim categories as of January 2025. Any compounded enclomiphene is therefore dispensed under the 503A framework based on a patient-specific prescription, not under an FDA approval, and its eligibility could change.

Where the male-use evidence comes from

In randomized Phase II and Phase III trials by Wiehle and Kaminetsky, oral enclomiphene citrate raised serum testosterone, LH, and FSH while preserving sperm counts, whereas men using testosterone gel showed sharply reduced sperm counts. This evidence comes from relatively small, short-term studies in secondary hypogonadism. Enclomiphene is not FDA-approved as a fertility treatment, and these findings should not be read as a promise that it will preserve or restore fertility for any individual. Separately, clomiphene citrate (Clomid) is FDA-approved only for ovulation induction in anovulatory or oligo-ovulatory women; its use in men for low testosterone or hypogonadism is off-label.

What is TRT?

TRT means exogenous testosterone for men with symptomatic, confirmed low testosterone. Diagnosis is not based on symptoms alone. It requires at least two early-morning total-testosterone measurements that are low (the AUA threshold is 300 ng/dL; the Endocrine Society uses 264 ng/dL) plus consistent signs and symptoms, ideally using the same lab and assay for serial measurements. TRT uses FDA-approved testosterone products, which are administered as injections, gels, or pellets depending on the product. Compounded testosterone, by contrast, is not FDA-approved. TRT is not appropriate for age-related or lifestyle “low T” without a clear diagnosis confirmed by labs.

A central trade-off with TRT involves fertility. Exogenous testosterone suppresses LH and FSH and intratesticular testosterone, which impairs spermatogenesis and can cause testicular atrophy and infertility, including azoospermia in a substantial share of men. For this reason, the AUA and ASRM recommend against testosterone monotherapy in men who are trying to conceive. In some cases, clinicians manage this by co-administering hCG (for example, low-dose hCG) to help maintain intratesticular testosterone. This is a clinician-managed, often off-label strategy and is not a guarantee that fertility or testicular volume will be preserved.

Monitoring on TRT

TRT requires ongoing lab monitoring under a licensed clinician. That typically includes total (and free) testosterone; hematocrit and hemoglobin, because of the risk of polycythemia (a hematocrit above 54% generally prompts dose reduction or phlebotomy); PSA, particularly in men over 40, to screen before and during therapy; and estradiol. Follow-up is commonly at two to three months and then periodically or annually. FDA-approved testosterone products also carry FDA labeling content. Topical gels retain a boxed warning about virilization from secondary exposure to children, and labels address abuse and dependence (testosterone is a Schedule III substance). Following the TRAVERSE trial, the FDA removed the prior cardiovascular boxed warning in 2025 and instead added blood-pressure (hypertension) information to the labels, so cardiovascular risk is no longer presented as boxed-warning content.

Comparing risks and monitoring

Both options carry risks that should be discussed with a provider, and neither is risk-free. We do not present either as safer or better than the other.

For SERM-class therapy like enclomiphene, the clomiphene citrate label warns that blurring or other visual symptoms (spots, flashes, or scintillating scotomata) may occur. These tend to increase with dose and duration and are usually reversible, but cases of prolonged visual disturbance have been reported, some after discontinuation, and they may be irreversible. The clomiphene label’s postmarketing adverse reactions also include thromboembolic events such as thrombophlebitis, phlebitis, deep venous thrombosis, and pulmonary embolism, though causality and frequency cannot be reliably established from voluntary reports.

For TRT, the main labeled and clinical concerns include elevated hematocrit (polycythemia), suppression of fertility and possible testicular atrophy, prostate and PSA considerations, the boxed warning on topical gels regarding secondary exposure to children, and abuse and dependence content in the labeling. Monitoring exists precisely to catch and manage these issues early.

Who might each suit?

Choosing between these approaches is an individualized medical decision. Generally speaking, men who place a high priority on preserving fertility and spermatogenesis sometimes ask their provider about enclomiphene because, in small short-term studies, it raised testosterone while preserving sperm counts. Men with classical, organic, confirmed hypogonadism may be candidates for FDA-approved TRT, sometimes paired with hCG when fertility is a concern. Because enclomiphene is not FDA-approved and male use is off-label, and because both carry meaningful risks, only a licensed provider can determine whether either is appropriate for you after reviewing your labs, history, and goals.

How Revive approaches this

Revive Longevity is a provider-centered platform. We do not sell outcomes, and we do not claim any compounded product is FDA-approved or that it will raise your testosterone, restore your fertility, or treat any disease. Our role is to connect you with a licensed provider who reviews your labs, symptoms, and goals and determines whether a prescription is appropriate, including ongoing monitoring. If treatment is appropriate, your provider can discuss options such as enclomiphene (a compounded product that is not FDA-approved; male use is off-label), TRT using FDA-approved testosterone products for appropriate candidates, and HCG (a clinician-managed, often off-label option), where your provider determines it is clinically appropriate.

If you want to understand the process before committing, see how it works and our pricing. To talk with a licensed provider about whether enclomiphene or TRT may fit your situation, start by reviewing enclomiphene and how it works. Nothing here is medical advice, and these products are prescription only.

Frequently asked questions

The following answers are educational and are not a substitute for advice from a licensed provider.

Is enclomiphene FDA-approved?

No. Enclomiphene citrate is not an FDA-approved drug, and no enclomiphene product, compounded or manufactured, has FDA approval for any indication, including low testosterone, hypogonadism, or fertility. The only branded enclomiphene product, Androxal, received an FDA Complete Response Letter in December 2015 and was later discontinued. On the FDA Section 503A bulk drug substances list, which is periodically revised, enclomiphene citrate has been placed in Category 1 (under evaluation); this is not an approval, the PCAC voted against adding it to the final 503A Bulks List on June 8, 2022, and the status is unsettled. Confirm the current status with the latest FDA list before relying on it.

How is enclomiphene different from TRT?

Enclomiphene is an oral SERM that is intended to stimulate your body’s own production of LH, FSH, and testosterone, and in small short-term studies it preserved sperm counts. TRT supplies testosterone from outside the body, which can suppress LH, FSH, and intratesticular testosterone and impair spermatogenesis, sometimes causing testicular atrophy. The AUA and ASRM recommend against testosterone monotherapy in men trying to conceive. Which approach, if any, may suit you is a decision for a licensed provider based on your labs, symptoms, and goals.

Does enclomiphene preserve fertility?

In small, short-term randomized studies in men with secondary hypogonadism, oral enclomiphene raised testosterone, LH, and FSH while preserving sperm counts, whereas testosterone gel sharply reduced sperm counts. However, enclomiphene is not FDA-approved as a fertility treatment, the evidence is limited, and results vary. It should not be presented as a proven way to preserve or restore fertility for any individual.

What are the main risks of each option?

For SERM-class therapy like enclomiphene, the clomiphene citrate label warns about visual disturbances such as blurring, spots, flashes, or scintillating scotomata, which can be prolonged and in some cases irreversible, even after stopping; postmarketing reports also include thromboembolic events. For TRT, concerns include elevated hematocrit (polycythemia), fertility suppression and possible testicular atrophy, and prostate and PSA considerations; topical gels carry a boxed warning about secondary exposure to children, and labels address abuse and dependence. Both require provider oversight, and neither is risk-free.

How is low testosterone diagnosed before TRT?

TRT is for men with symptomatic, confirmed low testosterone, not for age-related or lifestyle “low T” without a clear diagnosis. Diagnosis generally requires at least two early-morning total-testosterone measurements that are low (the AUA uses a 300 ng/dL threshold; the Endocrine Society uses 264 ng/dL) along with consistent signs and symptoms, ideally using the same lab and assay. Your provider will also set up ongoing monitoring, including testosterone, hematocrit, PSA, and estradiol.

Can fertility be protected during TRT?

Sometimes. Some clinicians co-administer hCG, such as low-dose hCG, to help maintain intratesticular testosterone during TRT. This is a clinician-managed, often off-label strategy and is not a guarantee that fertility or testicular volume will be preserved. If conceiving is a priority, discuss it with your provider before starting any therapy.